Although this seems conflicting with EZH2 ability to enhance proliferation, the proliferative capacity of a tumor does not necessarily correlates with aggressiveness or stage of the disease, as recently exemplified with the pediatric-type follicular lymphoma, an indolent type of follicular lymphoma with high proliferation index.34, 35 Moreover, proliferative tumors respond better to chemotherapy as a higher number of cells are in cycling and can be targeted, as all patients included in the PRIMA trial received rituximab chemotherapy as induction regimen. This evidence concerns the gene EZH2 and neoplasm.